New Opportunities for Targeting the Androgen Receptor in Prostate Cancer

Overview

Journal Cold Spring Harb Perspect Med

Specialty General Medicine

Date 2018 Mar 14

PMID 29530945

Citations 12

Authors

Margaret M Centenera

Luke A Selth

Esmaeil Ebrahimie

Lisa M Butler

Wayne D Tilley

Affiliations

Soon will be listed here.

Abstract

Recent genomic analyses of metastatic prostate cancer have provided important insight into adaptive changes in androgen receptor (AR) signaling that underpin resistance to androgen deprivation therapies. Novel strategies are required to circumvent these AR-mediated resistance mechanisms and thereby improve prostate cancer survival. In this review, we present a summary of AR structure and function and discuss mechanisms of AR-mediated therapy resistance that represent important areas of focus for the development of new therapies.

Citing Articles

Inceptor correlates with markers of prostate cancer progression and modulates insulin/IGF1 signaling and cancer cell migration.

Wissmiller K, Bilekova S, Franko A, Lutz S, Katsburg M, Gulde S Mol Metab. 2023; 71:101706.

PMID: 36931467 PMC: 10074927. DOI: 10.1016/j.molmet.2023.101706.

BMX controls 3βHSD1 and sex steroid biosynthesis in cancer.

Li X, Berk M, Goins C, Alyamani M, Chung Y, Wang C J Clin Invest. 2023; 133(2).

PMID: 36647826 PMC: 9843047. DOI: 10.1172/JCI163498.

Heat Shock Protein 90 (HSP90) Inhibitors as Anticancer Medicines: A Review on the Computer-Aided Drug Discovery Approaches over the Past Five Years.

Magwenyane A, Ugbaja S, Amoako D, Somboro A, Khan R, Kumalo H Comput Math Methods Med. 2022; 2022:2147763.

PMID: 35685897 PMC: 9173959. DOI: 10.1155/2022/2147763.

Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis.

Katleba K, Lombard A, Tsamouri M, Baek H, Nishida K, Libertini S Cancer Lett. 2021; 504:49-57.

PMID: 33549708 PMC: 7943249. DOI: 10.1016/j.canlet.2021.01.029.

Epigenetic modification-dependent androgen receptor occupancy facilitates the ectopic TSPY1 expression in prostate cancer cells.

Leng X, Liu M, Tao D, Yang B, Zhang Y, He T Cancer Sci. 2020; 112(2):691-702.

PMID: 33185915 PMC: 7894013. DOI: 10.1111/cas.14731.

References

Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K . Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res. 2002; 8(10):3276-84. View

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

Asim M, Massie C, Orafidiya F, Pertega-Gomes N, Warren A, Esmaeili M . Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. J Natl Cancer Inst. 2015; 108(5). PMC: 4849803. DOI: 10.1093/jnci/djv371. View

Chen S, Smith D . Hop as an adaptor in the heat shock protein 70 (Hsp70) and hsp90 chaperone machinery. J Biol Chem. 1998; 273(52):35194-200. DOI: 10.1074/jbc.273.52.35194. View

Gillis J, Selth L, Centenera M, Townley S, Sun S, Plymate S . Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget. 2013; 4(5):691-704. PMC: 3742830. DOI: 10.18632/oncotarget.975. View

Trotta A, Need E, Butler L, Selth L, OLoughlin M, Coetzee G . Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client. J Mol Endocrinol. 2012; 49(2):57-68. DOI: 10.1530/JME-11-0152. View

Biron E, Bedard F . Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer. J Steroid Biochem Mol Biol. 2015; 161:36-44. DOI: 10.1016/j.jsbmb.2015.07.006. View

Taplin M, Bubley G, Shuster T, FRANTZ M, Spooner A, Ogata G . Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995; 332(21):1393-8. DOI: 10.1056/NEJM199505253322101. View

Quayle S, Mawji N, Wang J, Sadar M . Androgen receptor decoy molecules block the growth of prostate cancer. Proc Natl Acad Sci U S A. 2007; 104(4):1331-6. PMC: 1783142. DOI: 10.1073/pnas.0606718104. View

10.

Attard G, Parker C, Eeles R, Schroder F, Tomlins S, Tannock I . Prostate cancer. Lancet. 2015; 387(10013):70-82. DOI: 10.1016/S0140-6736(14)61947-4. View

11.

Clinckemalie L, Vanderschueren D, Boonen S, Claessens F . The hinge region in androgen receptor control. Mol Cell Endocrinol. 2012; 358(1):1-8. DOI: 10.1016/j.mce.2012.02.019. View

12.

Pratt W, Toft D . Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood). 2003; 228(2):111-33. DOI: 10.1177/153537020322800201. View

13.

Claessens F, Gewirth D . DNA recognition by nuclear receptors. Essays Biochem. 2004; 40:59-72. DOI: 10.1042/bse0400059. View

14.

Miyake H, Chi K, Gleave M . Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res. 2000; 6(5):1655-63. View

15.

Glass C, Rosenfeld M . The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000; 14(2):121-41. View

16.

Zhu M, Horbinski C, Garzotto M, Qian D, Beer T, Kyprianou N . Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010; 70(20):7992-8002. PMC: 2978028. DOI: 10.1158/0008-5472.CAN-10-0585. View

17.

Lamoureux F, Thomas C, Yin M, Kuruma H, Beraldi E, Fazli L . Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res. 2011; 71(17):5838-49. DOI: 10.1158/0008-5472.CAN-11-0994. View

18.

Azad A, Zoubeidi A, Gleave M, Chi K . Targeting heat shock proteins in metastatic castration-resistant prostate cancer. Nat Rev Urol. 2014; 12(1):26-36. DOI: 10.1038/nrurol.2014.320. View

19.

Attard G, Belldegrun A, de Bono J . Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 2005; 96(9):1241-6. DOI: 10.1111/j.1464-410X.2005.05821.x. View

20.

Welti J, Nava Rodrigues D, Sharp A, Sun S, Lorente D, Riisnaes R . Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016; 70(4):599-608. PMC: 5015575. DOI: 10.1016/j.eururo.2016.03.049. View